ABSTRACT Radiation therapy for head and neck cancer results in severe secondary side-effects in salivary glands. We previously demonstrated that the administration of IGF1 preserves or restores salivary gland function following radiation. Based on these findings, we propose to study the effect of IGF1 on human head and neck carcinoma cells. Head and neck tumor cells treated with radiation have significant reductions in tumor cell survival, as measured by MTT and crystal violet assays, regardless of IGF1 pre-treatment. Head and neck squamous carcinoma cell xenografts treated with concurrent radiation+IGF1 also exhibit significant tumor growth delay; however, growth rates are elevated compared with those in irradiated xenografts. In contrast, administration of IGF1 after radiation treatment has no effect on tumor xenograft growth rates. Analysis of these data suggests that localized delivery may be required for concurrent therapy to prevent secondary side-effects of radiotherapy, while post-therapy administration of IGF1 could be considered for the restoration of salivary function. Abbreviations: IGF1, insulin-like growth factor 1; MTT, 2,2,2-Tribromoethanol; CV, crystal violet; IGFR, insulin-like growth factor receptor; HN, head and neck.
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InTRODuCTIOn
R adiotherapy for head and neck cancer patients can result in significant damage to surrounding non-tumor tissue, leading to decreased quality of life for patients. These secondary side-effects can include decreased saliva production, dysphagia, oral mucositis, malnutrition, and increased oral infections (Grundmann et al., 2009) . Radiation-induced xerostomia is one of the most common secondary side-effects and affects over 40,000 patients in the United States each year. New technologies such as intensity-modulated radiation therapy (IMRT) have been shown to increase parotid gland sparing; however, patients still experience some of the secondary side-effects of radiation up to 6 mos after therapy (Jensen et al., 2010) .
Recent studies have suggested that several growth factors may be used as radioprotectants for non-diseased tissue during radiation therapy (Grundmann et al., 2009) . Insulin-like growth factor 1 (IGF1) is a potent activator of Akt in salivary acinar cells, leading to a suppression of DNA damage-induced apoptosis (Limesand et al., 2003) . In previous studies, we demonstrated that IGF1 can suppress radiation-induced salivary gland apoptosis and preserve physiological function following single or fractionated radiation treatment . Utilization of IGF1 in a post-radiation therapy model results in restored stimulated salivary flow rates .
While protection of normal tissues exposed to radiation is important for reducing side-effects, it is equally important to assess the effects of these protective therapies on the tumor response to treatment. In this study, we evaluated the effect of treatment with IGF1 on the radiation response of human head and neck squamous carcinoma cells in vitro and in vivo to better understand how IGF-type therapies could improve therapeutic gain.
Head and neck Tumor Cell Radiation Response Occurs in the Presence of IGF1
number was assessed by crystal violet and MTT assays as previously described (Tosetti et al., 2003) .
Tumor Xenograft Initiation
All in vivo experiments were carried out by the Experimental Mouse Shared Service at the University of Arizona. NCr nude mice were obtained from Taconic Laboratories (Rensselaer, NY, USA) and were maintained in accordance with the protocols approved by the University of Arizona Institutional Animal Care and Use Committee. Mice were anesthetized with 2% isoflurane in 2 L/min oxygen, and 10 x 10 6 UMSCC1 cells (embedded in matrigel) were subcutaneously injected into the flanks of NCr nude mice. Tumor volume was determined according to the formula: [(width) 2 x length]/2 (Burd and Wachsberger, 2007) . Individual tumor volumes were measured 3X/wk and used to calculate the mean tumor volume for each day; results were plotted on a line graph. Nonirradiated mice received intravenous injections of vehicle (PBS + 10 mg/mL BSA) or 5 µg IGF1 (GroPrep, Adelaide, Australia) on the corresponding radiation treatment days.
Radiation Treatment
Cell lines were treated with a single 2-Gy or 5-Gy dose in a Cobalt-60 Teletherapy unit (Atomic Energy of Canada Ltd). Mice with xenografts were pair-matched by tumor volumes and weighed prior to treatment. Animals were treated intravenously with vehicle or 5 µg IGF1 5 min prior to each radiation treatment, as previously described . Mice receiving post-therapy IGF1 were treated with radiation on days 1-5 and injected intravenously with 5 µg IGF1 on days 6-10. Radiation treatment was conducted under anesthesia, as described above, and consisted of 2 Gy/day (days 1-5) focused onto the xenograft with the use of a Cobalt-60 Teletherapy unit. The 5-Gy radiation dose was chosen based on previous work in the salivary glands demonstrating that this dose caused elevated levels of p53 protein, activation of apoptosis, and loss of salivary function (Limesand et al., 2006 , and the 2-Gy dose was chosen based on work utilizing fractionated radiation .
Histology
Tumors were surgically excised, fixed in 10% neutral buffered formalin for 24 hrs, transferred to 70% ethanol, and embedded in paraffin. Tissue sections were cut to 4 µm and processed for standard staining with hematoxylin and eosin by the Histology Service Laboratory in the Department of Cell Biology and Anatomy at the University of Arizona. Tumor sections were observed by standard light microscopy, and photomicrographs were taken with a Leica DM5500 with a 4-megapixel Pursuit camera.
Immunohistochemistry
Tumors selected for activated caspase-3 staining were removed 24 hrs after final radiation and processed for histology. Unstained tissue sections were stained for activated caspase-3 (Cell Signaling Technology, Beverly, MA, USA) as previously described (Limesand et al., 2006) . UMSCC1 xenograft proliferation indices were determined on day 38 with unstained tissue sections and anti-PCNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) immunohistochemistry, as previously described .
IGF mRnA and Protein
Tumors were surgically excised 24 hrs after the completion of radiotherapy and divided in half. Total RNA and protein lysate preparation from each half was conducted as previously described (Mitchell et al., 2010) . IGFR expression was determined by real-time RT/PCR with the following primers from IDT (Coralville, IA, USA): forward, 5′-ACTGAAGCCGAGAA GCAGGC-3′; and reverse, 5′-CTGCTTCGGCTGGACATGG T-3′. IGF1 analysis utilized primers from Qiagen (Alameda, CA, USA). Immunoblots were probed with anti-IGFR (Fisher, Pittsburgh, PA, USA), anti-IGFR-β (Santa Cruz Biotechnology), and anti-tubulin (Fisher) antibodies.
Statistics
In vitro comparisons of CV and MTT data were accomplished by a one-way ANOVA followed by a Bonferroni test with adjustment for the number of pairwise comparisons. For tumor analysis, we determined the average growth rate by establishing a linear regression for each tumor (Burd and Wachsberger, 2007) and comparing the group means. All tumors with a starting volume between 250 and 600 mm 3 were included in the growth rate analysis. Statistical comparisons were generated by a one-way ANOVA followed by a Newman-Keuls Multiple Comparison post hoc test. Statistical analysis and graphical generation of data were completed with GraphPad Prism software (version 5.0, San Diego, CA, USA).
RESulTS

Reductions in Hn Tumor Cell Viability following γ-radiation in the Presence of IGF1
To understand the effect of IGF1 on the radiation response of human HN tumor cells, we assessed levels of cell survival using a crystal violet (CV) assay following single radiation doses of 2 Gy and 5 Gy (Fig. 1a) . IGF1 concentration was based on the amount necessary for suppression of apoptosis in salivary acinar cells (Limesand et al., 2003) . There was a 46% and 61% reduction in cell survival of UMSCC1 following radiation (2 and 5 Gy, respectively), which was significantly lower than that in non-irradiated controls (Fig. 1a ). Pre-treatment of UMSCC1 with IGF1 did not significantly affect survival, since there was also a 50-54% decrease in cell survival (Fig. 1a) . We confirmed the CV assay results using metabolic activity by MTT assay following γ-radiation, which would also take into account sterilized cells (Fig. 1b) . Treatment of UMSCC1 with 2 or 5 Gy resulted in an 18% and 47% decrease, respectively, in metabolic activity. Similarly, treatment with IGF1 prior to radiation resulted in a 17% and 39% reduction in metabolic activity. Significant differences in metabolic activity with IGF1 pre-treatment were detected only at the higher radiation dose (5 Gy; Fig. 1b) ; however, there was no significant difference in overall cell survival (Fig. 1a) . Evaluation of UMSCC23, CAL 27, A-253, and FaDU cell lines yielded similar results (Figs. 1c, 1d) to UMSCC1. Analysis of these data suggests that significant decreases in overall cell survival following radiation occur with concurrent IGF1 treatment in a diverse set of HN cancer cell lines.
uMSCC1 Xenografts Exhibited a Radiation Response in the Presence of IGF1
To further confirm our in vitro findings, we evaluated the effect of IGF1 in vivo using an NCr nude mouse xenograft model ( Fig. 2a ). UMSCC1 tumor xenografts with an average volume of 389 mm 3 were treated with radiation (2 Gy/ day; days 1-5) or radiation plus concurrent IGF1. The starting group volumes were not significantly different from one another (p = 0.77). The IGF1 concentration was based on the amount necessary for suppression of radiation-induced apoptosis and preservation of salivary gland function . No significant increase in weight loss or normal toxicity was observed in any group after treatment with radiation, IGF1, or the combination (data not shown). IGF1 alone had no significant effect on tumor growth (p = 0.43 vs. control). Tumor xenografts treated with radiation (IR) had significantly reduced growth rates when compared with control tumors (p = 0.049; Fig. 2b ). Administration of IGF1 prior to radiation (IGF1+IR) attenuated the radiation response (p = 0.054 vs. IR), but still resulted in a significant tumor growth delay (p = 0.047 vs. IGF1). We have established a restoration model of radiation-induced salivary dysfunction utilizing post-therapy injections of IGF1 ; therefore, we evaluated tumor growth when IGF1 was administered on days 6-10 (post-IGF1; Fig. 2a ). Tumors receiving injections of IGF1 after radiation treatment (post-IGF1) had significantly reduced growth rates (p = 0.047 vs. control) that were similar to those in mice receiving radiation (p = 0.33 vs. IR). Secondary metastases were not observed in any of the treatment groups; however, this was not quantitatively addressed, and additional studies would be required for formal evaluation.
Analysis of these data suggests that concurrent IGF1+radiation treatment had a slightly adverse effect on radiation response, but did not abolish it; however, post-therapy IGF1 does not affect UMSCC1 tumor response to radiation in vivo.
Apoptosis and IGFR levels Remained unchanged following Exposure to Ionizing Radiation
The extent of apoptosis in UMSCC1 xenografts was evaluated by immunohistochemical staining for activated caspase-3 24 hrs after the last radiation treatment (2 Gy/day for 5 days). Apoptosis levels in UMSCC1 xenografts were similar across all treatment groups and did not increase significantly following exposure to ionizing radiation (Fig. 3a) . IGFR mRNA and protein levels were determined in xenograft tumors at this time-point, with no Figure 1 . Reductions in HN tumor cell viability following γ-radiation in the presence of IGF1. UMSCC1 cells were exposed to 2-Gy and 5-Gy radiation with and without IGF1 pre-treatment and analyzed by crystal violet survival assay (a) or MTT metabolic assay (b) 96 hrs after radiation. Data were collected from 3 independent experiments normalized to control and displayed as the mean ± SEM. UMSCC23, CAL 27, A-253, and FaDU cells were exposed to 5-Gy radiation with and without IGF1 pre-treatment and analyzed by crystal violet survival assay (c) or MTT metabolic assay (d) 96 hrs after radiation. Significant differences (p < 0.05) were determined by an ANOVA followed by Bonferroni's multiple comparison test. Treatment groups with the same letters are not significantly different from each other.
differences between treatment groups (Figs. 3b, 3c ). In addition, there was no change in IGF-1 expression in these tissues.
Histological Analysis
We also evaluated tumor tissue architecture 38 days after the last radiation dose by H&E staining (Figs. 4a-4d ). Most tumor xenografts were moderately differentiated squamous cell carcinomas with areas of obvious squamous differentiation, including keratohyalin granules, intercellular bridging, and increasing glycogenation with maturation. There was a moderate amount of chronic and acute inflammation in most tumors. No broad sections of necrosis were seen. Comparisons between groups did not reveal any differences in the differentiation or morphology of the tumors or amount and type of inflammation. The degree of mitotic activity was also similar between the treatment groups, which was confirmed with PCNA immunohistochemistry (data not shown).
DISCuSSIOn
Due to the mechanism of action of growth factors, it is generally anticipated that these molecules would enhance tumor growth and resistance to therapies. For example, recent studies have suggested that IGF1 may enhance tumor promotion in prostate cancers (Johansson et al., 2007; Saikali et al., 2008) . Furthermore, Keratinocyte Growth Factor (KGF) has been implicated in Tamoxifen resistance in human breast cancer MCF-7 cells (Chang et al., 2006) . Analysis of our in vitro data suggests that HN cancer cells pre-treated with IGF1 still exhibit significant reductions in cell viability following radiation (Fig. 1) when compared with non-irradiated controls. The cell lines evaluated were isolated from diverse sites in the oral cavity; however, similar radiation response profiles were observed. Therefore, UMSCC1 cells were chosen as a model for further in vivo analysis. In xenografts, concurrent radiation+IGF1 had a significant reduction of tumor growth when compared with IGF1 alone and did not alter the acute effects of radiation on tumor growth rates up to ~20 days after treatment (Fig. 2 ). However, after this timepoint, IGF1 pre-treated xenografts continue to grow, resulting in an attenuation of the overall effect of radiation. This may be related to the increased metabolic activity following higher doses of radiation with IGF1 in vitro (Fig. 1b) . Interestingly, post-therapy administration of IGF1 after radiation treatment has a significant reduction of tumor growth that is not statistically different from that of irradiated xenografts. These findings imply that the acute and chronic effects of growth factors may vary, depending upon the type of cancer, potentially due to the underlying mutations of that cancer.
In HN cancer, overexpression of the Epidermal Growth Factor receptor (EGFR), which occurs in ~ 90% of patients, has been associated with greater radioresistance, chemoresistance, and shorter disease-free survival in patients (Palme et al., 2004; Choong and Cohen, 2006) . Previous studies have shown that overexpression of EGFR leads to increased activation of the serine/threonine protein kinase, Akt (Amornphimoltham et al., 2004) . Akt is an effector of the PI3K pathway, which is a Post-IGF1 N = 6 2.5 -3.173 8.12 p = 0.047 vs. Control p = 0.33 vs. IR Figure 2 . Tumor growth rates of UMSCC1 xenografts. UMSCC1 xenografts were established in NCr nude mice as described in MATERIALS & METHODS. Animals in the IGF1 and radiation+IGF1 (IR+IGF1) groups were administered 5 µg IGF1 intravenously 5 min prior to each radiation treatment. Control and radiation (IR) animals received an intravenous injection of vehicle. Radiation treatment consisted of 2 Gy/day (days 1-5) focused on the xenograft (arrows, Fig. 2a ). Mice receiving post-therapy IGF1 (post-IGF1) were treated with radiation on days 1-5 and were injected with 5 µg IGF1 on days 6-10. In (a), the mean tumor volume is plotted over time. In (b), we determined average growth rate by establishing a linear regression for each individual tumor, and statistical comparisons and 95% confidence intervals were generated by a one-way ANOVA followed by a Newman-Keuls Multiple Comparison post hoc test.
pro-survival pathway often up-regulated in many cancers (Osaki et al., 2004) . While IGF1 activation of Akt is important to the survival of salivary acinar cells (Limesand et al., 2003) , it is possible that this pathway is maximally activated in HN cancer cells, due to the overexpression of EGFR. However, utilization of therapies targeting EGFR (e.g., Gefitinib) in combination with radiation may alter the effect of IGF1 depicted in this study. IGF1-treated HN tumor cells significantly responded to radiation, but the response was attenuated. This study evaluated the effects of systemic administration of IGF1 based on previous work on radiation-induced salivary gland dysfunction; however, this could be modified to intraductal injections of IGF1 to limit the treatment specifically to the salivary glands. Even though there is potential to reduce adverse sideeffects and increase therapeutic gain, the effect of concurrent IGF1 on tumor clearance may preclude the utilization of this growth factor for the prevention of radiation-induced xerostomia. It will be necessary to identify the specific molecules in the IGF1 pathway that mediate preservation and restoration of salivary gland function and avoid tumor cell interactions. These targeted therapies would have a greater potential to provide protection to the surrounding normal tissues without altering the effectiveness of anti-cancer regimens.
